Accéder au contenu
Merck
Toutes les photos(1)

Documents

1357056

USP

Leflunomide Related Compound B

United States Pharmacopeia (USP) Reference Standard

Synonyme(s) :

2-Cyano-3-hydroxy-N-(4-trifluoromethylphenyl)crotonamide

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule empirique (notation de Hill):
C12H9F3N2O2
Numéro CAS:
108605-62-5
Poids moléculaire :
270.21
Numéro MDL:
MFCD00910058
Code UNSPSC :
41116107
ID de substance PubChem :
329750239
Nomenclature NACRES :
NA.24

Qualité

pharmaceutical primary standard

Famille d'API

leflunomide

Fabricant/nom de marque

USP

Application(s)

pharmaceutical (small molecule)

Format

neat

Chaîne SMILES 

O=C(/C(C#N)=C(O)/C)NC1=CC=C(C(F)(F)F)C=C1

InChI

1S/C12H9F3N2O2/c1-7(18)10(6-16)11(19)17-9-4-2-8(3-5-9)12(13,14)15/h2-5,18H,1H3,(H,17,19)/b10-7-

Clé InChI

UTNUDOFZCWSZMS-YFHOEESVSA-N

Informations sur le gène

human ... DHODH(1723)

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Description générale

Leflunomide Related Compound B (2-Cyano-3-hydroxy-N-(4-trifluoromethylphenyl)crotonamide is a malononitrilamide which is a water soluble metabolite of Leflunomide. It is considered as a noncompetitive inhibitor of dihydro-orotate dehydrogensae. This metabolite has been reported to initially target activated lymphocytes.

Remarque sur l'analyse

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Autres remarques

Sales restrictions may apply.

Produit(s) apparenté(s)

Réf. du produit
Description
Tarif

Y0000654

Leflunomide, European Pharmacopoeia (EP) Reference Standard

Y0000674

Leflunomide for peak identification, European Pharmacopoeia (EP) Reference Standard

1356960

Leflunomide, United States Pharmacopeia (USP) Reference Standard

Y0000487

Leflunomide impurity A, European Pharmacopoeia (EP) Reference Standard

1357045

Leflunomide Related Compound A, United States Pharmacopeia (USP) Reference Standard

1357067

Leflunomide Related Compound C, United States Pharmacopeia (USP) Reference Standard

PHR1378

Leflunomide, Pharmaceutical Secondary Standard; Certified Reference Material

PHR1568

Leflunomide Related Compound A, Pharmaceutical Secondary Standard; Certified Reference Material

BP1233

Leflunomide, British Pharmacopoeia (BP) Reference Standard

Pictogrammes

Exclamation mark
GHS07

Mention d'avertissement

Warning

Mentions de danger

H302

Classification des risques

Acute Tox. 4 Oral

Code de la classe de stockage

11 - Combustible Solids

Classe de danger pour l'eau (WGK)

WGK 3

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Mingchang Zhang et al.
Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban, 28(3), 364-368 (2008-06-20)
The effects of A771726, the active metabolite of leflunomide, on experimental rat corneal neovascularization (NV) in vivo and on cultured human umbilical vein endothelial cells in vitro were studied. The corneal NV was induced by alkali burn in 40 SD
Jae Youl Cho
Archives of pharmacal research, 31(2), 160-166 (2008-03-28)
FTY720 is a derivative of ISP-1 (myriocin), a fungal metabolite of the Chinese herb Iscaria sinclarii, with agonistic effect for sphingosine-1-phosphate receptor. In this study, we examined the potential adverse effect of FTY720 in terms of cell cytotoxicity and the
Xiaoming Tang et al.
Biological & pharmaceutical bulletin, 32(6), 963-967 (2009-06-02)
During the resolution phase of hepatic fibrosis, a crucial mechanism is the apoptosis of activated hepatic stellate cells (HSCs). It is necessary to find more anti-fibrosis drugs that would modulate HSCs to be more susceptible to apoptotic stimuli. Here we
Deborah Cowen et al.
Bioorganic & medicinal chemistry letters, 20(3), 1284-1287 (2009-12-26)
A series of mono- and di-substituted N-arylaminomethylene malonates have been used to probe the potential of utilizing additional H-bonding contacts in the ubiquinone binding channel, for selective inhibition between either human or Plasmodium DHODH. Altered 'head' group functionalities have been
Quee Ming Seah et al.
Drug metabolism letters, 2(3), 153-157 (2009-04-10)
We used immortalized human hepatocytes to study the bioactivation of leflunomide and the metabolic degradation to its major metabolite, A77 1726. Both leflunomide and A77 1726 caused a time- and concentration-dependent increase in LDH release. The cytotoxicity of leflunomide, but
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique